Article Figures & Tables
Tables
- Table 1:
Demographic characteristics, liver/hepatitis B virus test results, fibrosis and antiviral therapy of Canadians with chronic hepatitis B, by province
Variable Province; no. (%) of patients* (95% CI) Total
n = 9380BC
n = 1535Alta.
n = 1814Sask.
n = 179Man.
n = 1051Ont.
n = 4637Que.
n = 132NS
n = 19NL
n = 13Age, yr, mean (median) 49.1 (48) (48.80–49.36) 52.7‡ (53) (52.01–53.35) 45.6‡ (44) (45.01–46.21) 44.3 (41) (42.22–46.42) 46.6‡ (46) (45.76–47.37) 50.0‡ (50) (49.62–50.44) 49.6 (47) (47.28–51.84) 40.9‡ (36) (34.47–47.32) 44.5 (50) (37.73–51.20) Male sex 5193 (55.4) (54.35–56.37) 864 (56.3) (53.76–58.78) 919 (50.7)‡ (48.33–52.99) 106 (59.2) (51.62–66.42) 558 (53.1) (50.02–56.14) 2642 (57.0)‡ (55.54–58.41) 81 (61.4) (52.47–69.59) 13 (68.4) (43.50–86.44) 10 (76.9) (45.98–93.84) Born in Canada 80 (0.8) (0.68–1.07) 5 (0.3)‡ (0.12–0.81) 4 (0.2)‡ (0.07–0.60) 3 (1.7)‡ (0.43–5.21) 0 (0.0)‡ 68 (1.5)‡ (1.15–1.87) 0 (0.0)‡ 0 (0.0)‡ 0 (0.0) Immigrant status missing 7063 (75.3) (74.41–76.17) 939 (61.2)‡ (58.68–63.61) 1398 (77.1)‡ (75.05–78.97) 84 (46.9)‡ (39.49–54.50) 693 (65.9)‡ (62.97–68.79) 3797 (81.9)‡ (80.74–82.98) 132 (100.0)‡ (96.48–100.00) 7 (36.8)‡ (17.23–61.37) 13 (100.0) (71.66–100.00) Asian 5803 (61.9) (60.87–62.85) 1120 (73.0)‡ (70.65–75.16) 1109 (61.1)‡ (58.84–63.38) 97 (54.2)‡ (46.60–61.59) 252 (24.0)‡ (21.45–26.70) 3198 (69.0)‡ (67.61–70.29) 13 (9.8)‡ (5.56–16.57) 11 (57.9) (33.97–78.88) 3 (23.1)‡ (6.16–54.02) Black 916 (9.8) (9.18–10.39) 16 (1.0)‡ (0.62–1.73) 272 (15.0)‡ (13.40–16.74) 34 (19.0)‡ (13.68–25.67) 76 (7.2)‡ (5.77–9.01) 498 (10.7)‡ (9.87–11.67) 17 (12.9)‡ (7.90–20.09) 2 (10.5) (1.84–34.54) 1 (7.7)‡ (0.40–37.91) White 914 (9.7) (9.16–10.37) 32 (2.1)‡ (1.45–2.97) 94 (5.2)‡ (4.23–6.33) 24 (13.4)‡ (8.95–19.49) 21 (2.0)‡ (1.27–3.09) 664 (14.3)‡ (13.33–15.37) 79 (59.8)‡ (50.94–68.17) 0 (0.0) 0 (0.0)‡ Ethnicity missing 1522 (16.2) (15.49–16.99) 343 (22.3)‡ (20.30–24.53) 305 (16.8)‡ (15.14–18.63) 16 (8.9)‡ (5.36–14.35) 690 (65.6)‡ (62.68–68.51) 144 (3.1)‡ (2.63–3.66) 12 (9.1)‡ (5.00–15.67) 4 (21.0) (6.97–46.10) 8 (61.5)‡ (32.28–84.87) HBeAg-positive 1240 (13.2) (12.54–13.93) 232 (15.1)‡ (13.38–17.03) 217 (12.0)‡ (10.52–13.57) 30 (16.8)‡ (11.76–23.23) 27 (2.6)‡ (1.73–3.77) 697 (15.0)‡ (14.02–16.10) 30 (22.7)‡ (16.08–31.00) 3 (15.8) (4.17–40.49) 4 (30.8) (10.36–61.12) HBeAg status missing 2584 (27.5) (26.65–28.47) 713 (46.4)‡ (43.93–48.98) 680 (37.5)‡ (35.26–39.77) 14 (7.8)‡ (4.50–13.03) 745 (70.9)‡ (68.02–73.60) 421 (9.1)‡ (8.28–9.95) 2 (1.5)‡ (0.26–5.92) 4 (21.0) (6.97–46.10) 5 (38.5) (15.13–67.72) HBV DNA level < 2000 IU/mL 2319 (24.7) (23.85–25.61) 881 (57.4)‡ (54.87–59.88) 582 (32.1)‡ (29.95–34.3) 87 (48.6)‡ (41.12–56.15) 480 (45.7)‡ (42.63–48.74) 252 (5.4)‡ (4.81–6.14) 27 (20.4)‡ (14.13–28.54) 10 (52.6)‡ (29.50–74.79) 0 (0.0) HBV DNA level missing 6560 (69.9) (68.99–70.86) 654 (42.6)‡ (40.12–45.13) 731 (40.3)‡ (38.04–42.60) 92 (51.4)‡ (43.85–58.88) 571 (54.3)‡ (51.26–57.37) 4385 (94.6)‡ (93.86–95.19) 105 (79.5)‡ (71.46–85.87) 9 (47.4)‡ (25.21–70.50) 13 (100.0) (71.66–100.00) Alanine transaminase level, U/L, mean (median)† 40.1 (27) (37.43–42.86) 33.4 (25)‡ (30.67–36.10) 38.0 (28) (33.11–42.81) 36.9 (27) (27.00–46.89) 51.3‡ (27) (42.32–60.32) 39.2 (30) (36.34–41.98) 43.8 (28) (33.43–54.10) 30.1‡ (26) (23.66–36.58) NA Stage F3–4 fibrosis 324 (3.4) (3.10–3.85) 103 (6.7)‡ (5.53–8.11) 113 (6.2)‡ (5.18–7.47) 7 (3.9) (1.72–8.21) 4 (0.4)‡ (0.12–1.04) 96 (2.1)‡ (1.69–2.53) 1 (0.8)‡ (0.04–4.77) 0 (0.0)‡ 0 (0.0)‡ Fibrosis data missing 5120 (54.6) (53.57–55.60) 102 (6.6)‡ (5.47–8.04) 962 (53.0)‡ (50.70–55.35) 93 (52.0) (44.40–59.43) 1004 (95.5)‡ (94.05–96.66) 2807 (60.5)‡ (59.11–61.94) 120 (90.9)‡ (84.33–95.00) 19 (100.0)‡ (79.08–100.00) 13 (100.0)‡ (71.66–100.00) Lamivudine prescription (at any time) 1434 (15.3) (14.57–16.04) 386 (25.1)‡ (23.01–27.41) 71 (3.9)‡ (3.09–4.94) 1 (0.6)‡ (0.03–3.55) 14 (1.3)‡ (0.76–2.28) 958 (20.6)‡ (19.51–21.86) 2 (1.5)‡ (0.26–5.92) 1 (5.3)‡ (0.28–28.11) 1 (7.7) (0.40–37.91) Tenofovir disoproxil prescription (at any time) 1655 (17.6) (16.88–18.43) 376 (24.5)‡ (22.38–26.74) 408 (22.5)‡ (20.60–24.50) 17 (9.5)‡ (5.80–15.01) 35 (3.3)‡ (2.36–4.65) 788 (17.0) (15.93–18.11) 30 (22.7) (16.08–31.00) 1 (5.3)‡ (0.28–28.11) 0 (0.0) Entecavir prescription (at any time) 548 (5.8) (5.38–6.34) 80 (5.2)‡ (4.18–6.48) 199 (11.0)‡ (9.59–12.52) 0 (0.0)‡ 9 (0.8) (0.42–1.68) 259 (5.6) (4.95–6.30) 1 (0.8)‡ (0.04–4.77) 0 (0.0)‡ 0 (0.0) Treatment data missing 139 (1.5) (1.25–1.75) 0 (0.0)‡ 0 (0.0)‡ 66 (36.9)‡ (29.89–44.43) 0 (0.0)‡ 70 (1.5) (1.19–1.91) 0 (0.0)‡ 3 (15.8)‡ (4.17–40.49) 0 (0.0) Note: CI = confidence interval, HBeAg = hepatitis B e-antigen, HBV = hepatitis B virus, NA = not available.
↵* Except where noted otherwise.
↵† Data missing for 5487 patients overall: 112 from British Columbia, 1378 from Alberta, 74 from Saskatchewan, 32 from Manitoba, 3875 from Ontario, 14 from Quebec and 2 from Nova Scotia.
↵‡ p < 0.05 for difference between the value for a given province, and the national total minus the value for that province.
- Table 2:
Demographic characteristics, liver/hepatitis B virus test results, fibrosis and treatment of Canadians with chronic hepatitis B, by hepatitis B virus genotype
Variable Genotype; no. (%) of patients* (95% CI) A–E
n = 980A
n = 218B
n = 278C
n = 243D
n = 157E
n = 84Age, yr, mean (median) 46.2 (44) (45.36–47.01) 44.8 (43) (43.00–46.70) 48.3‡ (47) (46.81–49.77) 49.2‡ (49) (47.61–50.81) 44.1‡ (42) (41.90–46.27) 37.9‡ (37.5) (36.14–39.67) Male sex 533 (54.4) (51.21–57.53) 121 (55.5) (48.64–62.17) 143 (51.4) (45.41–57.43) 127 (52.3) (45.79–58.66) 95 (60.5) (52.38–68.12) 47 (56.0) (44.72–66.63) Born in Canada 3 (0.3) (0.08–0.97) 0 (0.0)‡ 1 (0.4) (0.02–2.30) 2 (0.8)‡ (0.14–3.26) 0 (0.0) 0 (0.0) Immigrant status missing 678 (69.2) (66.17–72.04) 120 (55.0)‡ (48.18–61.73) 208 (74.8) (69.21–79.73) 194 (79.8)‡ (74.12–84.58) 105 (66.9) (58.86–74.05) 51 (60.7) (49.43–71.01) Asian 389 (39.7) (36.63–42.84) 78 (35.8)‡ (29.50–42.57) 161 (57.9)‡ (51.86–63.74) 119 (49.0)‡ (42.55–55.43) 28 (17.8)‡ (12.37–24.92) 3 (3.6)‡ (0.93–10.81) Black/African/Caribbean 128 (13.1) (11.05–15.37) 43 (19.7)‡ (14.78–25.76) 1 (0.4)‡ (0.02–2.30) 5 (2.0)‡ (0.76–5.00) 20 (12.7)‡ (8.14–19.22) 59 (70.2)‡ (59.13–79.47) White 104 (10.6) (8.79–12.75) 6 (2.8)‡ (1.12–6.18) 36 (12.9)‡ (9.35–17.61) 38 (15.6)‡ (11.43–20.96) 22 (14.0)‡ (9.18–20.66) 2 (2.4)‡ (0.41–9.14) Ethnicity missing 333 (34.0) (31.03–37.05) 91 (41.7)‡ (35.17–48.61) 80 (28.8)‡ (23.61–34.55) 81 (33.3)‡ (27.51–39.69) 63 (40.1)‡ (32.48–48.26) 18 (21.4)‡ (13.52–32.00) HBeAg positive 140 (14.3) (12.19–16.67) 23 (10.6)‡ (6.95–15.60) 33 (11.9) (8.43–16.40) 61 (25.1)‡ (19.88–31.13) 12 (7.6)‡ (4.19–13.27) 11 (13.1) (7.03–22.64) HBeAg status missing 233 (23.8) (21.17–26.59) 64 (29.4)‡ (23.50–35.96) 62 (22.3) (17.64–27.75) 53 (21.8)‡ (16.89–27.64) 33 (21.0)‡ (15.10–28.39) 21 (25.0) (16.47–35.85) HBV DNA level < 2000 IU/mL 341 (34.8) (31.83–37.88) 91 (41.7)‡ (35.17–48.61) 80 (28.8)‡ (23.61–34.55) 76 (31.3) (25.58–37.57) 62 (39.5) (31.88–47.62) 32 (38.1) (27.91–49.38) HBV DNA level missing 554 (56.5) (53.36–59.65) 121 (55.5)‡ (48.64–62.17) 168 (60.4)‡ (54.40–66.17) 140 (57.6) (51.12–63.86) 80 (51.0) (42.90–58.97) 45 (53.6) (42.41–64.41) Alanine transaminase level, U/L, mean (median)† 38.7 (28) (33.09–44.23) 34.6 (27) (29.84–39.37) 32.0‡ (28) (28.80–35.16) 52.7 (28) (31.06–74.31) 28.6‡ (24) (25.42–31.73) 51.8 (31) (30.80–72.73) Stage F3–4 fibrosis 27 (2.8) (1.86–4.04) 3 (1.4)‡ (0.36–4.30) 8 (2.9)‡ (1.34–5.81) 11 (4.5)‡ (2.40–8.18) 2 (1.3) (0.22–5.00) 3 (3.6) (0.93–10.81) Fibrosis data missing 636 (64.9) (61.81–67.87) 166 (76.1)‡ (69.82–81.53) 154 (55.4)‡ (49.34–61.30) 154 (63.4)‡ (56.94–69.38) 105 (66.9) (58.86–74.05) 57 (67.8) (56.66–77.40) Lamivudine prescription (at any time) 28 (2.8) (1.94–4.16) 1 (0.4)‡ (0.02–2.92) 11 (4.0) (2.09–7.17) 11 (4.5) (2.40–8.18) 5 (3.2) (1.18–7.66) 0 (0.0) Tenofovir disoproxil prescription (at any time) 155 (15.8) (13.62–18.29) 18 (8.2)‡ (5.11–12.94) 36 (12.9) (9.35–17.61) 68 (28.0)‡ (22.53–34.15) 25 (15.9) (10.76–22.81) 8 (9.5) (4.50–18.41) Entecavir prescription (at any time) 35 (3.6) (2.54–4.99) 2 (0.9)‡ (0.16–3.63) 15 (5.4) (3.16–8.93) 12 (4.9) (2.70–8.68) 5 (3.2) (1.18–7.66) 1 (1.2) (0.06–7.37) Treatment data missing 13 (1.3) (0.74–2.32) 0 (0.0)‡ 5 (1.8) (0.66–4.39) 5 (2.0) (0.76–5.00) 2 (1.3) (0.22–5.00) 1 (1.2) (0.06–7.37) Note: CI = confidence interval, HBeAg = hepatitis B e-antigen, HBV = hepatitis B virus.
↵† Data missing for 381 patients: 70 with genotype A, 105 with genotype B, 103 with genotype C, 70 with genotype D and 33 with genotype E.
↵‡ p < 0.05 for difference between a given genotype, and the total for all other genotypes minus the value for that genotype.
- Table 3:
Demographic characteristics, liver/hepatitis B virus test results, fibrosis and treatment of Canadians with chronic hepatitis B, by sex and age
Variable No. (%) of patients* (95% CI) Men
n = 5193Women
n = 4187Age < 40 yr
n = 2621Age ≥ 40 yr
n = 6759Age, yr, mean (median) 49.9‡ (50) (49.56–50.30) 48.0‡ (47) (47.59–48.46) 32.7§ (33) (32.48–32.85) 55.4§ (54) (55.19–55.7) Male sex 5193 (100.0)‡ (99.91–100.00) –‡ 1260 (48.1)§ (46.15–50.01) 3933 (58.2)§ (57.00–59.37) Born in Canada 47 (0.9) (0.67–1.21) 33 (0.8) (0.55–1.12) 22 (0.8)§ (0.54–1.29) 58 (0.8)§ (0.66–1.12) Immigrant status missing 3943 (75.9) (74.74–77.08) 3120 (74.5) (73.16–75.83) 1922 (73.3)§ (71.59–75.01) 5141 (76.1)§ (75.02–77.07) Asian 3147 (60.6)‡ (59.25–61.93) 2656 (63.4)‡ (61.95–64.89) 1510 (57.6)§ (55.69–59.51) 4293 (63.5)§ (62.35–64.66) Black/African/Caribbean 516 (9.9)‡ (9.14–10.79) 400 (9.6)‡ (8.69–10.49) 433 (16.5)§ (15.13–18.01) 483 (7.1)§ (6.55–7.79) White 562 (10.8)‡ (10.00–11.71) 352 (8.4)‡ (7.59–9.30) 168 (6.4)§ (5.52–7.43) 746 (11.0)§ (10.30–11.81) Ethnicity missing 834 (16.1)‡ (15.08–17.09) 688 (16.4)‡ (15.33–17.60) 427 (16.3)§ (14.91–17.77) 1095 (16.2)§ (15.33–17.11) HBeAg positive 659 (12.7)‡ (11.80–13.63) 581 (13.9)‡ (12.85–14.97) 578 (22.0)§ (20.49–23.70) 662 (9.8)§ (9.10–10.53) HBeAg status missing 1384 (26.6)‡ (25.46–27.88) 1200 (28.7)‡ (27.30–30.06) 747 (28.5)§ (26.79–30.28) 1837 (27.2)§ (26.12–28.26) HBV DNA level < 2000 IU/mL 1235 (23.8) (22.63–24.97) 1084 (25.9) (24.57–27.25) 681 (26.0)§ (24.32–27.72) 1638 (24.2)§ (23.22–25.28) HBV DNA level missing 3673 (70.7) (69.47–71.96) 2887 (69.0) (67.52–70.35) 1776 (67.8)§ (65.93–69.54) 4784 (70.8)§ (69.68–71.86) Alanine transaminase level, U/L, mean (median)† 48.2‡ (31) (43.45–52.86) 30.5‡ (22) (28.66–32.43) 42.5 (27) (36.27–48.67) 39.3 (27) (36.34–42.18) Stage F3–4 fibrosis 232 (4.5) (3.93–5.07) 92 (2.2) (1.78–2.70) 37 (1.4)§ (1.01–1.96) 287 (4.2)§ (3.78–4.76) Fibrosis data missing 2753 (53.0) (51.64–54.38) 2367 (56.5) (55.01–58.04) 1601 (61.1)§ (59.18–62.95) 3519 (52.1)§ (50.86–53.26) Lamivudine prescription (at any time) 926 (17.8)‡ (16.81–18.91) 508 (12.1)‡ (11.17–13.17) 217 (8.3)§ (7.27–9.42) 1217 (18.0)§ (17.10–18.95) Tenofovir disoproxil prescription (at any time) 1087 (20.9)‡ (19.84–22.07) 568 (13.6)‡ (12.55–14.65) 350 (13.4)§ (12.09–14.73) 1305 (19.3)§ (18.38–20.27) Entecavir prescription (at any time) 350 (6.7)‡ (6.08–7.46) 198 (4.7)‡ (4.12–5.43) 93 (3.5)§ (2.89–4.35) 455 (6.7)§ (6.15–7.36) Treatment data missing 90 (1.7)‡ (1.40–2.14) 49 (1.2)‡ (0.88–1.56) 35 (1.3)§ (0.95–1.87) 104 (1.5)§ (1.26–1.87) Note: CI = confidence interval, HBeAg = hepatitis B e-antigen, HBV = hepatitis B virus.
↵* Except where noted otherwise.
↵† Data missing for 3078 men, 2422 women, 1556 patients aged less than 40 years and 3944 patients aged 40 years or more.
↵‡ p < 0.05 for difference between men and women.
↵§ p < 0.05 for difference between patients aged less than 40 years and those aged 40 years or more.